Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 9,935 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single-arm Clear all

Conditions: Mitral Regurgitation
Interventions: Cardiac MRI with or without contrast dye, Blood sample; Diagnostic Test
Lead sponsor: Dipan Shah; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Atlanta, Georgia • Houston, Texas

Conditions: Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions: Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Salem, Massachusetts

Conditions: Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Pemetrexed, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1081
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 694 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: RAD001, PKC412; Drug
Lead sponsor: Richard Stone, MD; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Essential Tremor, Parkinson's Disease
Interventions: Clinician programmer electrode screening mode tool; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Albany, New York • San Antonio, Texas • Spokane, Washington

Conditions: Acne
Interventions: apremilast; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cytomegalovirus (CMV)
Interventions: Maribavir; Drug
Lead sponsor: Takeda; Industry
Eligibility: Up to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Wilmington, Delaware • St. Petersburg, Florida • Chicago, Illinois + 4 more

Conditions: Renal Impairment
Interventions: RO7079901; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 2 more

Conditions: Melanoma
Interventions: Pembrolizumab, Vibostolimab, Gebasaxturev, MK-4830, Favezelimab + Pembrolizumab, ATRA; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 11
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more

Conditions: Colorectal Cancer, Appendix Cancer, Peritoneal Carcinomatosis
Interventions: Oxaliplatin; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 99 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Prostate Cancer
Interventions: AAA617; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 24
States / cities: Scottsdale, Arizona • Orange, California • Santa Monica, California + 19 more

Conditions: Myelodysplastic Syndromes
Interventions: lenalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 31
States / cities: Scottsdale, Arizona • Tucson, Arizona • Rancho Mirage, California + 22 more

Conditions: Type 1 Diabetes Mellitus
Interventions: rhGAD65, Placebo; Drug
Lead sponsor: Diamyd Therapeutics AB; Industry
Eligibility: 10 Years to 20 Years
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 43
States / cities: Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 40 more

Conditions: Diabetic Foot Ulcers (DFUs)
Interventions: Meso Wound Matrix; Device
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Pembroke Pines, Florida • Ford City, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Bladder Cancer
Interventions: FDG PET/MR; Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Asthma in Children
Interventions: Clinical decision support + education (CDS+), Control; Behavioral · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 18 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non Muscle Invasive Bladder Cancer
Interventions: CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside; Biological · Other
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: La Jolla, California • Orange, California • Tampa, Florida + 9 more

Conditions: Drug Safety
Interventions: Placebo, VIA-3196; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Pediatric Surgical Procedures
Interventions: Behavioral Treatment; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 12 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Brighton, Michigan

Conditions: Right Bundle-Branch Block
Interventions: Optimization of CRT Device; Diagnostic Test
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 89 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Little Rock, Arkansas • Detroit, Michigan

Conditions: Advanced Solid Tumors
Interventions: darinaparsin; Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Lafayette, Indiana • Dallas, Texas • Houston, Texas

Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Clinical Observation, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography; Procedure · Other · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer
Interventions: fluvastatin sodium, Breast Cancer Surgery Only - Arm III; Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 4
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 1 more

Conditions: Knee Arthroplasty
Interventions: Total Knee Arthroplasty, MAKO® Robot Assisted Medial Knee Arthroplasty, RESTORIS Multicompartmental Knee System, Depuy Knee Replacement System, Stryker® Knee Replacement System; Procedure · Device
Lead sponsor: Northwest Surgical Specialists, Vancouver; Other
Eligibility: 21 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Vancouver, Washington

Search by objective public record fields.

Effect of MitraClip on Acute and Chronic Reverse Cardiac Remodeling Assessed by CMR: The MITRA-REVERSE Study

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Evaluation of the Infinity Deep Brain Stimulation Electrode Screening Mode Tool

Apremilast in the Treatment of Moderate to Severe Acne

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

Effect of Meso Wound Matrix in the Treatment of DFUs

Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer

SMART Implementation-Effectiveness Trial 1

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Adolescent Surgery Roadmap Feasibility and Acceptability Study

Adaptive Cardiac Resynchronization Therapy in Patients With RBBB

Study of Oral Darinaparsin in Patients With Advanced Solid Tumors

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer

Clinical and Economic Comparison of Robot Assisted Versus Manual Knee Replacement